Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment schemas with Lutathera in progressive intestinal well-differentiated neuroendocrine tumors
2021-001306-30Phase 2Active
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Aug 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised trial of lutetium Lu 177 dotatate in apudoma (NET) (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Disease Control Rate at 6 months. Started Aug 2021; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2021-001306-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001306-30.